OBJECTIF: Évaluer le rôle de l’endostatine, un nouveau marqueur anti-angiogénique, pour prédire le risque de prééclampsie (PE). METHODES: Il s’agit d’une étude cas témoins nichée dans deux cohortes prospectives. Les échantillons sanguins étaient collectés entre 11 et 17 semaines puis entre 18 et 26 semaines d’aménorrhée. L’hypertension gestationnelle était définie par une tension artérielle supérieure ou égale à 140/90mmHg à 2 reprises. Les cas de prééclampsie étaient définis par une hypertension gestationnelle associée à une protéinurie supérieure ou égale à 0.3 g /24h après 20 semaines de grossesse. La concentration d’endostatine était mesurée par une technique d’ELISA. Les résultats étaient exprimés en multiples de la médiane (MoM) et ajustés pour l’âge maternel, l’âge gestationnel, l’ethnie, et la cohorte d’origine. Une régression logistique était utilisée pour calculer des odds ratios (OR) ajustés et prédire le risque de PE. RESULTATS: Au total nous avons étudié 77 PE et 150 témoins chez des grossesses uniques. Parmi les PE 21 étaient de survenue précoce, avec un diagnostic avant 34 semaines et 41 étaient des PE sévères. Les cas avaient un IMC plus élevé que les témoins et étaient plus souvent Africaines. Les taux médians d’endostatine étaient significativement plus élevés chez les PE que chez les témoins au 1er trimestre (94.2 versus 90.7 ng/ml, p=0.004) et 2ème trimestre (105.8 versus 99.3 ng/ml p=0.002). Le taux d’endostatine entre 18 et 26 semaines était même plus élevé chez les patientes qui développaient une PE précoce. Lorsque l’endostatine était supérieure au 75èmepercentile (exprimée en MoM), le OR ajusté était de 1.33 95IC [0.68-2.58] à 11-17 semaines et 1.77 [0.94-3.34] à 18-26 semaines. L’OR ajusté pour les PE précoces était 3.51 [1.18-10.43] entre 11-17 semaines et 2.17 [0.67-7.06] entre 18-26 semaines. CONCLUSIONS: Un taux élevé d’endostatine dès le 1er trimestre est associé à une augmentation du risque de PE et surtout d’un risque de prééclampsie précoce. Toutefois l’endostatine seule a une trop faible valeur prédictive pour avoir une utilité clinique. / OBJECTIVE: To evaluate a new anti-angiogenic factor, endostatin, in relation to the risk of preeclampsia (PE). STUDY DESIGN: We performed a case control study nested in two separate prospective cohorts. Serum samples were collected at 11-17 weeks and 18-26 weeks of gestation. Maternal endostatin levels were measured by ELISA. Results were expressed as multiples of the median (MoM) adjusted for maternal age, gestational age, ethnicity, and cohort of origin. Logistic regression was used to calculate adjusted odds ratios (aORs) of PE. RESULTS: A total of 77 PE and 150 controls of singleton pregnancies were studied, including 21 early-onset PE (diagnosis before 34 weeks) and 41 severe PE. Cases had a higher pre-pregnancy BMI and were more likely of African ethnicity than controls. Endostatin levels were significantly higher in women with PE compared to controls at both the first and second trimester (median 94.2 vs. 90.7 ng/ml p=0.004 and 105.8 vs. 99.3 ng/ml p= 0.002 respectively). Endostatin levels were even higher in women with early-onset PE. At a cut-off level of 75th percentile of endostatin MoMs, the adjusted ORs for PE were 1.33, 95CI [0.68-2.58] at 11-17 weeks and 1.77 [0.94-3.34] at 18-26 weeks. The aORs for early-onset PE were 3.51 [1.18-10.43] at 11-17 weeks and 2.17 [0.67-7.06] at 18-26 weeks, respectively. CONCLUSION: Higher endostatin levels as early as in the first trimester may indicate an increased risk of subsequent PE, especially early onset PE. However endostatin alone has a poor predictive value for clinical usefulness.

The goals of the thesis were to, in pig models, (1) assess manganese-enhanced magnetic resonance imaging (MEMRI) in the characterization of acute and chronic ischemia-induced myocardial infarction (MI), (2) characterize cryoinjury-induced MI with contrast-enhanced MRI and optical methods, and (3) observe the effects of locally released angiogenic factors on the repair of cryoinjury-induced MI. Firstly, after acute MI was established by occlusion of the coronary artery branches, the pig hearts were isolated and mounted onto an ex vivo perfusion system inside a 7T magnet. After administration of MnCl2, T1-weighted MR images showed gradual enhancement of signal intensity within the normal myocardium, whereas the ischemic counterpart remained hypointense. During chronic MI progression, the intensity increased slowly after exposure to MnCl2 within the infarcted myocardium. Secondly, a new MI model was tested via direct 2-min contact of left ventricular epicardium with a liquid nitrogen-cooled aluminum bar. Subsequent in vivo Gd-enhanced MRI showed a uniform hypointense area (~10 mm in depth) surrounded by a hyperintense rim. Histology showed erythrocytes embolism within the cryolesion with a thin necrotic rim neighboring the normal myocardium. Four weeks later, the cryoinjured myocardium was replaced by scar tissue. Thirdly, in vivo MEMRI was tested on this cryoinjury model. After intravenous administration of MnCl2 via intermittent bolus or continuous infusion, normal myocardium showed prolonged hyperintense, which led to significant signal contrast between it and cryoinjured myocardium. Continuous infusion scheme minimized hemodynamic fluctuation. Finally, angiogenic therapy was assessed by anchoring of vascular growth factors-loaded alginate beads or adipose-derived stem cells (ADSCs)-loaded agarose patch on top of the cryoinjured myocardium. Gd-enhanced MRI revealed (1) growth of new tissue wrapping the growth factors-loaded alginate beads and (2) higher perfusion within the ADSCs-treated cryoinjured myocardium as compared with the growth factors-treated counterpart. Histological and fluorescent microsphere examination revealed that ADSCs induced more significant growth of mature microvasculature within the cryoinjured myocardium. These results indicate that MnCl2 could characterize MI ex vivo and in vivo. Epicardial implantation of ADSCs-loaded agarose hydrogel can induce angiogenesis within the cryoinjured myocardium, a form of MI with similar progression features as that induced by ischemia.

Hämangiosarkome, maligne endotheliale Neoplasien, werden bei den Haussäugetieren am häufigsten beim Hund beobachtet und treten bei diesem vor allem in Milz und rechtem Herzohr auf. Anhand ihrer Wachstumsmuster werden sie in kapilläre, kavernöse und solide wachsende Tumoren eingeteilt (PULLEY u. STANNARD 1990, HARRY u. PALEOLOG 2003). Die Prognose kaniner Hämangiosarkome der Milz ist schlecht, wobei in der Literatur nach Splenektomie mediane Überlebenszeiten von 19-240 Tagen angegeben werden (JOHNSON et al. 1989, OGILVIE et al. 1996, SPANGLER u. KASS 1997, WOOD et al. 1998) und auch Praktiker von sehr stark variierenden Überlebenszeiten berichten. Die Eignung verschiedener Parameter (z.B. adjuvante Chemotherapie, klinisches Staging) zur prognostischen Beurteilung wurde bereits von zahlreichen Autoren untersucht (BROWN et al. 1985, SORENMO et al. 1993, WOOD et al. 1998). Studien zum eventuellen Einfluss des Wachstumsmusters auf die Variabilität der Überlebenszeiten existieren bisher jedoch nicht. Darüber hinaus können Hämangiosarkome der Milz auch diagnostisch eine Herausforderung darstellen. Dies ist zum Einen bedingt durch die hohe Anfälligkeit der Milz gegenüber einer raschen Autolyse, zum Anderen erschwert die sehr variable Histomorphologie in einigen Fällen eine sichere Diagnosestellung. Mit dem immunhistologischen Nachweis klassischer Endothelzellmarker wie von Willebrand Faktor und CD31 kann in den meisten Fällen die Diagnose gesichert werden. Besonders bei schlecht differenzierten Hämangiosarkomen, erweisen sich die genannten Marker oftmals als z. T. unzuverlässig (VON BEUST et al. 1988, GAMLEM u. NORDSTOGA 2008). Bei rein solide wachsenden Neoplasien kann der Transkriptionsfaktor Fli-1 hilfreich bei der Diagnose sein (STEIGER et al. 2003). Pro- und anti-angiogene Faktoren steuern in einem streng regulierten, stufenweise ablaufenden Prozess die Entstehung neuer Blutgefäße aus präexistenten Gefäßen – die Angiogenese (KERBEL et al. 1998, CARMELIET et al. 1998, RAK et al. 2000, JOUSSEN et al. 2003, DISTLER et al. 2003). Diese Faktoren konnten u.a. in Neoplasien und deren versorgenden Gefäßen nachgewiesen werden (RESTUCCI et al. 2002, RESTUCCI et al. 2004). Ziel der Studie ist (I) die Untersuchung der Überlebenszeiten von Hunden mit lienalen Hämangiosarkomen unter Berücksichtigung des Wachstumsmusters und weiterer Parameter, (II) wird mittels vergleichender immunhistologischer Untersuchungen die Eignung klassischer Endothelzellmarker sowie angiogener Faktoren und deren Rezeptoren zum Nachweis neoplastischer Endothelzellen überprüft. Der Vergleich des Expressionsverhaltens der genannten Marker zwischen Hämangiosarkomen und nicht-neoplastischen Endothelzellen gibt eventuell Hinweise auf die biologische Wertigkeit der Neoplasien.

The goals of the thesis were to, in pig models, (1) assess manganese-enhanced magnetic resonance imaging (MEMRI) in the characterization of acute and chronic ischemia-induced myocardial infarction (MI), (2) characterize cryoinjury-induced MI with contrast-enhanced MRI and optical methods, and (3) observe the effects of locally released angiogenic factors on the repair of cryoinjury-induced MI. Firstly, after acute MI was established by occlusion of the coronary artery branches, the pig hearts were isolated and mounted onto an ex vivo perfusion system inside a 7T magnet. After administration of MnCl2, T1-weighted MR images showed gradual enhancement of signal intensity within the normal myocardium, whereas the ischemic counterpart remained hypointense. During chronic MI progression, the intensity increased slowly after exposure to MnCl2 within the infarcted myocardium. Secondly, a new MI model was tested via direct 2-min contact of left ventricular epicardium with a liquid nitrogen-cooled aluminum bar. Subsequent in vivo Gd-enhanced MRI showed a uniform hypointense area (~10 mm in depth) surrounded by a hyperintense rim. Histology showed erythrocytes embolism within the cryolesion with a thin necrotic rim neighboring the normal myocardium. Four weeks later, the cryoinjured myocardium was replaced by scar tissue. Thirdly, in vivo MEMRI was tested on this cryoinjury model. After intravenous administration of MnCl2 via intermittent bolus or continuous infusion, normal myocardium showed prolonged hyperintense, which led to significant signal contrast between it and cryoinjured myocardium. Continuous infusion scheme minimized hemodynamic fluctuation. Finally, angiogenic therapy was assessed by anchoring of vascular growth factors-loaded alginate beads or adipose-derived stem cells (ADSCs)-loaded agarose patch on top of the cryoinjured myocardium. Gd-enhanced MRI revealed (1) growth of new tissue wrapping the growth factors-loaded alginate beads and (2) higher perfusion within the ADSCs-treated cryoinjured myocardium as compared with the growth factors-treated counterpart. Histological and fluorescent microsphere examination revealed that ADSCs induced more significant growth of mature microvasculature within the cryoinjured myocardium. These results indicate that MnCl2 could characterize MI ex vivo and in vivo. Epicardial implantation of ADSCs-loaded agarose hydrogel can induce angiogenesis within the cryoinjured myocardium, a form of MI with similar progression features as that induced by ischemia.

L’ensemble de ce travail vise à étudier les mécanismes de résistance aux thérapies anti-angiogéniques dans le traitement du cancer du rein à cellules claires (ccRCC). Nous avons mis en évidence que le bévacizumab (BVZ), un anticorps monoclonal humanisé anti-VEGF utilisé en clinique, accélère la croissance de ccRCC humain chez la souris nude. Ce modèle mime la phase d’échappement souvent observée chez les patients. Le traitement BVZ induit de la lymphangiogenèse associée à une surexpression du VEGF-C. Les cellules tumorales après traitement possèdent également des capacités d’invasion accrues. Ainsi, le traitement BVZ pourrait faciliter la progression tumorale et la formation de métastases dans les ccRCC. Le traitement entraine également une diminution de l’expression d’une phosphatase membranaire, la phospho-tyrosine phosphatase récepteur kappa (PTPR)impliquée dans le contrôle de l’activité de récepteurs à activité tyrosine kinase, comme le récepteur de l’EGF, du PDGF et de l’HGF. Ces récepteurs régulent la prolifération et la migration cellulaire. Le traitement BVZ faciliterait donc la croissance tumorale indépendante du VEGF. Enfin, le traitement induit une augmentation de la sécrétion de cytokines angiogéniques redondantes qui prennent le relais du VEGF, comme les cytokines CXCL7 et CXCL8, et facilitent le développement tumoral sous traitement BVZ. En particuliers, la cytokine CXCL7 et ses récepteurs CXCR1-2 ont un rôle central dans le développement des ccRCC. Cibler l’axe CXCL7/CXCR1-2 réduit efficacement la croissance tumorale. Les récepteurs cibles de PTPR, pour lesquels des inhibiteurs sont actuellement utilisés pour le traitement d’autres cancers, le VEGF-C et la cytokine CXCL7, pourraient donc constituer de nouveaux marqueurs prédictifs d’efficacité du BVZ et de nouvelles cibles thérapeutiques dans le traitement des ccRCC. La résistance au BVZ pourrait également s’expliquer par l’existence de formes "bénéfiques" anti-angiogéniques du VEGF qui sont reconnues par le BVZ avec la même affinité que les formes pro-angiogéniques. Nous avons mis en évidence qu’une immunisation prophylactique à l’aide d’un peptide spécifique du VEGF pro-angiogénique limite la croissance tumorale de ccRCC syngéniques de souris. De la même façon, en traitement curatif, l’utilisation d’anticorps spécifiques du VEGF pro-angiogénique bloque la croissance de ccRCC chez la souris nude sans induire les différents mécanismes d’échappement observés avec le BVZ. Ces résultats suggèrent la pertinence du ciblage spécifique des formes pro-angiogéniques de VEGF dans le traitement des ccRCC. / The aim of my work is to study resistance mechanisms to anti-angiogenic treatments of Clear Cell Renal Carcinoma (ccRCC). We observed that bevacizumab (BVZ) -a humanized monoclonal antibody targeting VEGF and currently used in the clinic- promotes the growth of human ccRCC xenografts in nude mice. This model mimics the “escape phase” widely observed in patients. BVZ treatment induces lymphangiogenesis and over-expression of VEGF-C. Tumor cells exposed to the treatment acquire an increased spreading capacity. Hence, BVZ might promote tumor progression and metastasis formation of ccRCC. Furthermore, this treatment decreases the expression of the receptor phosphor tyrosine phosphatase kappa (PTRP). This phosphatase is involved in the regulation of tyrosine kinase receptors controlling growth and migration, among others EGF, PDGF and HGF receptors. Thus, BVZ might promote tumor growth independently of VEGF. Moreover, the treatment increases secretion of redundant cytokines like CXCL7 and CXCL8. By their ability to exert similar effect as VEGF, these cytokines promote tumor development under BVZ treatment. In particular, CXCL7 and its receptors CXCR1 and CXCR2, play a central role in the development of ccRCC. Targeting this pathway efficiently reduces tumor growth. Target receptors of PTRP for which inhibitors are currently used for other cancers, VEGF-C and CXCL7 could therefore be regarded as new predictive markers for BVZ efficiency and may be considered as potential therapeutic targets. Resistance to BVZ could also be explained by the presence of "beneficial" forms of anti-angiogenic VEGF recognized by the BVZ with the same affinity as the pro-angiogenic forms. We have demonstrated that prophylactic immunization with a pro-angiogenic VEGF-specific peptide limits tumor growth of murine syngeneic ccRCC. Similarly, in curative therapy, antibodies specific for pro-angiogenic VEGF block growth of ccRCC in nude mice without inducing the escape mechanisms observed with BVZ. These results highlight the relevance of targeting such pro-angiogenic forms of VEGF for the treatment of ccRCC.

Le VEGF-A joue un rôle clé au cours de l’angiogenèse physiologique mais aussi de la néo-vascularisation tumorale essentielle à la croissance des tumeurs malignes. Le VEGF-A et ses récepteurs (VEGFR1/2) représentent une cible de première importance pour le développement de thérapies anti-tumorales, et un certain nombre de médicaments anti-angiogéniques (AAG) inhibant le VEGF-A ou ses récepteurs sont actuellement utilisés en clinique dans le traitement des carcinomes pulmonaires. Parmi les thérapies anti-angiogéniques ciblant le VEGF-A, on peut lister soit l’anticorps monoclonal anti-VEGF Bevacizumab (BVZ) ou bien les inhibiteurs pharmacologiques du domaine tyrosine kinase des VEGFR: les VEGFR-TKI. Seuls les patients porteurs d’adénocarcinomes pulmonaires peuvent bénéficier de thérapies AAG, les patients porteurs de carcinomes squameux présentant de sévères complications (hémorragies pulmonaires). Le sVEGFR1, est un variant tronqué du VEGFR1 qui ne contient que les premiers six motifs N-terminaux extracellulaires de type Ig du domaine extracellulaire et il est dépourvu des domaines transmembranaire et tyrosine kinase. Le sVEGFR1 a éte initialement considéré comme un facteur anti-angiogénique qui neutralise les fonctions du VEGF-A dans les cellules endothéliales. Les hauts niveaux ont été corrélés avec un mauvais pronostic et une mauvaise réponse aux thérapies dans plusieurs types de cancer. Nous avons montré in vitro dans 4 lignées cellulaires de SCC que le bevacizumab, ainsi que les inhibiteurs VEGF-TKI (Semaxanib, KI8751) augmentent les niveaux intra- et extra-cellulaires du sVEGFR1. Nous avons confirmé ces résultats in vivo dans des modèles murins de xénogreffes squameux induits par NCTU. De façon intérssante, l’augmentation du sVEGFR1 en réponse aux thérapies anti-angiogénique est spécifique aux modèles squameux et n’a pas été observée dans les modèles d’adénocarcinomes in vitro et in vivo. Sur le plan moléculaire, nous avons montré que le VEGF165 par l’intermédiaire de SOX2 régule l’expression du sVEGFR1 en réponse aux thérapiesAAG. De plus, nous avons identifié une boucle autocrine 1 intégrine / VEGFR1 / VEGFR2 par laquelle sVEGFR1 contrôle différentiellement la prolifération cellulaire et la survie, permettant notamment de distinguer les cellules SCC sensibles ou résistantes aux thérapies AAG. Enfin, dans une série de 77 cancers bronchiques non à petites cellules, nous avons montré que 11% et 44% des patients SCC expriment de bas ou de hauts nivaux de sVEGFR1 respectivement. Les hauts niveaux ont été corrélés avec des stades pTNM avancés. Dans l'ensemble, nos résultats sont la première preuve que les thérapies AAG augmentent l'expression du sVEGFR1 dans les cellules SCC. En outre, nos données mettent en évidence une fonction pro-tumorale inattendue de sVEGFR1 grâce à l'activation d'une boucle autocrine VEGFR/ β1 intégrine. Ces résultats pourraient aider à comprendre pourquoi les SCC répondent différemment aux AAG que les ADC et d'identifier les patients SCC qui pourraient etre éligibles à ces thérapies. / Vascular endothelial growth factors (VEGFs) and their receptors are regulators of physiological and pathological angiogenesis. In patients with squamous cell lung carcinoma (SCC), clinical trials evaluating anti-angiogenic therapies (AAG) have failed to identify strong benefits. Rather, these patients are at higher risk of bleeding complications when exposed to Bevacizumab (BVZ), a humanized monoclonal anti-VEGF-A antibody. The soluble VEGF receptor-1, namely sVEGFR1, is a truncated version of the cell membrane-spanning VEGFR1 that only retains the first six N-terminal Ig-like extracellular motifs of VEGFR1 owing to alternative splicing of its pre-mRNA. As a consequence, sVEGFR1 is mainly viewed as an anti-angiogenic factor that counteracts VEGF-A functions on endothelial cells. Moreover, high levels of sVEGFR1 were correlated with bad prognosis and bad response to therapies in many cancer types. Using various SCC cell lines, we showed that Bevacizumab as well as VEGFR-Tyrosine Kinase Inhibitors (Semaxanib, KI8751) increase the intra- and extra-cellular levels of sVEGFR1. We confirmed this up-regulation in NCTU-induced SCC murine tumorgrafts models treated with VEGFR-TKI (sunitinib) or anti-VEGFR2 (DC101). Of note, this effect was never observed in the lung adenocarcinoma histological sub-type (ADC), using either cell lines or a mouse model treated in the same conditions. At the molecular level, we identified the VEGF165 and SOX2 proteins as crucial upstream regulators of sVEGFR1 in response to AAG. Moreover, we unraveled an original and SOX2 proteins as crucial upstream regulators of sVEGFR1 in response to AAG. Moreover, we unraveled an original ines or a mouse model treato discriminate between AAG-sensitive or -resistant SCC cells. Finally, in a series of 77 Non Small Cell Lung Carcinoma, we provided the first description of a differential pattern of sVEGFR1 expression with 11% and 44% of SCC exhibiting no or high expression respectively, high levels of sVEGFR1 being correlated with advanced pTNM stages. As a whole, our results provide the first evidence that AAG therapies upregulate sVEGFR1 expression in SCC cells. In addition, our data highlight an unexpected pro-tumoral function of sVEGFR1 through the activation of a beta 1 integrin-dependent VEGFR autocrine loop. These results might help to understand why SCC are less responsive to anti-angiogenic drugs than ADC and to identify SCC patients eligible to these therapies.

Clinically, injuries affecting the spinal cord or peripheral nerves can leave those affected with severe disability and, at present, there are limited options for treatment. Peripheral nerve injury with a significant gap between the proximal and distal stumps is currently treated with autologous nerve grafting but this is limited by availability of donor nerve and has associated morbidities. In contrast, injuries to the spinal cord lead to an inhibitory environment caused by the glial cells and thereby, limit potential axonal regeneration. This thesis investigates the effects of human adipose derived stem cells (ASC) on regeneration after peripheral nerve and spinal cord injury in adult rats. Human ASC expressed various neurotrophic molecules and growth factor stimulation of the cells in vitro resulted in increased secretion of BDNF, GDNF, VEGF-A and angiopoietin-1 proteins. Stimulated ASC also showed an enhanced ability to induce capillary-like tube formation in an in vitro angiogenesis assay. In contrast to Schwann cells, ASC did not induce activation of astrocytes and supported neurite outgrowth from the adult rat sensory DRG neurons in culture. In a peripheral nerve injury model, ASC were seeded into a fibrin conduit, which was used to bridge a 10 mm rat sciatic nerve gap. After 2 weeks, ASC enhanced GAP-43 and ATF-3 expression in the spinal cord, reduced c-jun expression in the DRG and increased the vascularity of the fibrin nerve conduits. The animals treated with stimulated ASC showed an enhanced axon regeneration and reduced caspase-3 expression in the DRG. After transplantation into the injured C3-C4 cervical spinal cord. ASC continued to express neurotrophic factors and laminin and stimulated extensive ingrowths of 5HT-positive raphaespinal axons into the trauma zone. In addition, ASC induced sprouting of raphaespinal terminals in C2 contralateral ventral horn and C6 ventral horn on both sides. Transplanted cells also changed the structure and the density of the astroglial scar. Although the transplanted cells had no effect on the density of capillaries around the lesion site, the reactivity of OX42-positive microglial cells was markedly reduced.

O objetivo do atual trabalho, foi correlacionar os eventos celulares e teciduais com a expressão das proteínas VEGF, BMP-7, RANKL e OPG durante a osteogênese ectópica e ortotópica, induzida pela matriz óssea (MO) e dentinária (MD) alogênica. Matrizes alogênicas desmineralizada em HCl a 0,6N, obtidas de fêmur e incisivo de ratos, fori implantada entre as fáscias musculares da coxa e em defeito trans-ósseo de 8mm de diâmetro nos ossos parietais. As análises radiográfica e histomorfométrica da neoformação óssea e, a imunohistoquímica e o western blotting para as proteínas VEGF, BMP, RANKL e OPG, mostraram que: a) o volume da região do enxerto nos sítios ortotópicos reduziu 19% em 42 dias; b) em ambos tipos de enxerto e locais de implantação, ocorreu formação de tecido cartilaginoso e ósseo; c) nos sítios intramusculares, a reabsorção da matriz alogênica e a remodelação do tecido cartilaginoso, ósseo e medular foi mais acelerado, em relação a implantação ortotópico; d) o aumento na densidade de volume dos vasos sanguíneos e no número de osteoblastos/osteócitos e osteoclastos ocorreu simultaneamente e estava associado à maior reabsorção da matriz alogênica e à formação do tecido medular (hematopoiético); e) as proteínas VEGF, BMP-7, RANKL, OPG foram expressas em condrócitos, osteoblastos ativos, osteócitos recém aprisionados na matriz e em células estromais próximas aos osteoblastos ou às áreas da matriz alogênica reabsorvida; e f) a expressão das proteínas VEGF, BMP-7, RANKL e OPG foi maior no grupo MO. O pico de expressão dessas proteínas ocorreu nos períodos de 14 aos 21 dias no grupo da MO e 21 e 28 dias no grupo da MD. Concluímos que, a capacidade osteoindutora da matriz alogênica desmineralizada está relacionado a origem da matriz e ao sítio de implantação e que, as proteínas VEGF, BMP-7, RANKL e OPG estão associadas a maior reabsorção da matriz implantada, promovendo uma rápida e contínua liberação dos morfógenos contidos em seu interior que, induzem temporal e espacialmente a formação óssea/medular. / The aim of the present work was to correlate the cellular and tissue events with the expression of VEGF, BMP-7, RANKL and OPG during ectopic and orthotopic osteogenesis, induced by bone and dentin allogeneic matrix. Allogenic matrices obtained from femur and incisor of rats and demineralized in 0.6 N HCl were implanted into a intramuscular pocket and a 8mm-diameter bone defect in the skull. The radiographic and histomorphometric analysis of new bone formation, and immunohistochemistry and western blotting for VEGF, BMP, RANKL and OPG proteins, showed that: a) the total volume of the graft region in orthotopic site decreased 19% at 42 days b) in both graft types and implantation sites occurred formation of cartilaginous and bone tissues, c) in intramuscular sites, the resorption of allogenic matrix and remodeling of the new formed cartilage and bone were faster, in relation to orthotopic implantation sites; d) the increase in the volume density of blood vessels and in the number of osteoblasts/osteocytes and osteoclasts occurred simultaneously and was associated with greater reabsorption of the allogenic matrix and hematopoietic bone marrow formation; e) VEGF, BMP-7, RANKL, OPG proteins were expressed in chondrocytes, active osteoblasts, newly osteocytes confined and stromal cells located near the osteoblasts or in the surface of the reabsorbed matrix; and f) the VEGF, BMP-7, RANKL and OPG expression was higher in MO grafts than in the MD. The peak of expression of these proteins each occurred at 14 and 21 days in MO and 21 and 28 days in MD. We concluded that, the osteoinductive capacity of allogeneic demineralized matrix is related to matrix origin and implantation site and that the VEGF, BMP-7, RANKL and OPG proteins are associated with greater reabsorption of the implanted matrix, promoting rapid and continuous matrix-release morphogens that induces spatially and temporally the bone and bone marrow formation.

Die Bedeutung der angiogenen Faktoren „soluble fms-like tyrosine kinase-1“ (sFlt-1) und „placental growth factor“ (PIGF) in der Pathogenese der Präeklampsie (PE) ist in den letzten Jahren hinreichend belegt worden. Bei Patienten mit manifester PE lassen sich dramatisch hohe sFlt-1- bzw. sehr niedrige PlGF-Werte nachweisen. Mittlerweile konnte in Studien die sFlt-1/PlGF-Ratio als sensitiver Parameter ermittelt werden. Ziel der vorliegenden Arbeit ist es, die Zusammenhänge zwischen klinischen Parametern der manifesten Präeklampsie und der sFlt-1/PlGF-Ratio zu spezifizieren. Dabei soll geprüft werden, ob bei manifester PE die Höhe der sFlt-1/PlGF-Ratio vor Entbindung klinische Bedeutung hat und mit Parametern des Schwangerschaftsausgangs in Beziehung steht.

Indiana University-Purdue University Indianapolis (IUPUI) / EFFECTS OF DYNAMATRIX® ON ANGIOGENIC CYTOKINE EXPRESSION FROM HUMAN DENTAL PULP FIBROBLASTS: AN IN VITRO STUDY by Joseph Benjamin Adams Indiana University School of Dentistry Indianapolis, IN Introduction: An exogenous scaffold may lead to more predictable pulp tissue regeneration and continued root formation in a regenerative endodontic procedure. DynaMatrix® is a natural membrane scaffold made of porcine small intestine, currently used in periodontal regenerative surgeries. Objective: The purpose of this study was to investigate if human dental pulp fibroblasts (HDPFs) seeded on DynaMatrix® membrane would result in an increase in the expression of angiogenic cytokines. Materials and Methods: HDPFs (75,000 per well) were seeded in 6-well plates. Three groups were tested: Group 1 (C): HDPFs in 70 media only; Group 2 (M): DynaMatrix® (Cook Biotech, Indianapolis, IN) alone in media; and Group 3 (C+M): HDPFs seeded on DynaMatrix® membranes. After 72 hours of incubation in serum positive, the conditioned media were collected and analyzed for the expression of 20 angiogenic cytokines utilizing RayBiotech Inc., arrays per the manufacturer’s instruction. The data were analyzed by ANOVA. Results: Group M was significantly higher than C for bFGF (p = 0.0023). C+M was significantly higher than M for ANG (p = 0.0104); GRO (p = 0.0003); IFN-γ (p = 0.0023); IL-6 (p = 0.0003); IL-8 (p = 0.0003); Leptin (p = 0.0003); MCP-1 (p = 0.0104); TIMP-1 (p = 0.0190); TIMP-2 (0.0123). C was significantly higher than C+M for ANG (p = 0.0104); MCP-1 (p = 0.0104); and THPO (p = 0.0308). Cytokines such as b-FGF, ANG, and leptin promote angiogenesis, and stimulate migration and proliferation of cells. Conclusion: The cytokine expression profile from the cells seeded on DynaMatrix® suggests that it might be a suitable scaffold for regenerative endodontic procedures. It could improve vascularization by increasing angiogenic cytokines in the microenvironment of the treated root canal and supporting tissue regeneration.